EGFR and colorectal carcinoma: Activating mutations in RAS and hyper-expression of EGFR occur in approximately 50% and 80% of CRC cases, respectively, leading to the continuous activation of the PI3K/Akt/mTORC1 pathway (227, 228), which alters cancer metabolism (229).